BACKGROUND: Atopic dermatitis (AD) is a common skin disease that is characterized by recurrent episodes of itching. Filaggrin (FLG) loss-of-function (FLG null) mutations have been associated with an increased risk of AD. OBJECTIVE: We sought to evaluate the effect of individual FLG null mutations on the persistence of AD over time. METHODS: We evaluated a multiyear prospective cohort study of children with AD with respect to FLG null mutations (R501X, 2282del4, R2447X, and S3247X). We evaluated the association of these mutations with the persistence of AD symptoms over time with respect to reports of no symptoms of AD and whether topical medication was needed for symptom resolution. RESULTS: Eight hundred fifty-seven subjects were followed for 3684 person-years. One or more FLG null mutations were noted in 16.3% of subjects and specifically in 27.5% of white subjects and 5.8% of African American subjects. Subjects with an FLG null mutation were less likely (odds ratio [OR], 0.54; 95% CI, 0.41-0.71) to report that their skin was symptom free at any time compared with those without an FLG null mutation. The effect of these mutations was similar in white subjects (OR, 0.42; 95% CI, 0.31-0.57) and African-American subjects (OR, 0.53; 95% CI, 0.25-1.12; P = .62). Children with the R501X mutation (OR, 0.44; 95% CI, 0.22-0.88) were the least responsive to therapy. CONCLUSIONS: In a US cohort with AD, FLG null mutations were common. Children with FLG null mutations were more likely to have persistent AD. Although these mutations were more common in those of European ancestry, their effect on persistence was similar in those of African ancestry. Response to therapy was not uniform among children with FLG null mutations.
BACKGROUND:Atopic dermatitis (AD) is a common skin disease that is characterized by recurrent episodes of itching. Filaggrin (FLG) loss-of-function (FLG null) mutations have been associated with an increased risk of AD. OBJECTIVE: We sought to evaluate the effect of individual FLG null mutations on the persistence of AD over time. METHODS: We evaluated a multiyear prospective cohort study of children with AD with respect to FLG null mutations (R501X, 2282del4, R2447X, and S3247X). We evaluated the association of these mutations with the persistence of AD symptoms over time with respect to reports of no symptoms of AD and whether topical medication was needed for symptom resolution. RESULTS: Eight hundred fifty-seven subjects were followed for 3684 person-years. One or more FLG null mutations were noted in 16.3% of subjects and specifically in 27.5% of white subjects and 5.8% of African American subjects. Subjects with an FLG null mutation were less likely (odds ratio [OR], 0.54; 95% CI, 0.41-0.71) to report that their skin was symptom free at any time compared with those without an FLG null mutation. The effect of these mutations was similar in white subjects (OR, 0.42; 95% CI, 0.31-0.57) and African-American subjects (OR, 0.53; 95% CI, 0.25-1.12; P = .62). Children with the R501X mutation (OR, 0.44; 95% CI, 0.22-0.88) were the least responsive to therapy. CONCLUSIONS: In a US cohort with AD, FLG null mutations were common. Children with FLG null mutations were more likely to have persistent AD. Although these mutations were more common in those of European ancestry, their effect on persistence was similar in those of African ancestry. Response to therapy was not uniform among children with FLG null mutations.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: M Innes Asher; Stephen Montefort; Bengt Björkstén; Christopher K W Lai; David P Strachan; Stephan K Weiland; Hywel Williams Journal: Lancet Date: 2006-08-26 Impact factor: 79.321
Authors: Heather L Norton; Rick A Kittles; Esteban Parra; Paul McKeigue; Xianyun Mao; Keith Cheng; Victor A Canfield; Daniel G Bradley; Brian McEvoy; Mark D Shriver Journal: Mol Biol Evol Date: 2006-12-20 Impact factor: 16.240
Authors: Aileen Sandilands; Gráinne M O'Regan; Haihui Liao; Yiwei Zhao; Ana Terron-Kwiatkowski; Rosemarie M Watson; Andrew J Cassidy; David R Goudie; Frances J D Smith; W H Irwin McLean; Alan D Irvine Journal: J Invest Dermatol Date: 2006-06-29 Impact factor: 8.551
Authors: Alexander P Reiner; Christopher S Carlson; Elad Ziv; Carlos Iribarren; Cashell E Jaquish; Deborah A Nickerson Journal: Hum Genet Date: 2007-03-14 Impact factor: 5.881
Authors: Aileen Sandilands; Ana Terron-Kwiatkowski; Peter R Hull; Gráinne M O'Regan; Timothy H Clayton; Rosemarie M Watson; Thomas Carrick; Alan T Evans; Haihui Liao; Yiwei Zhao; Linda E Campbell; Matthias Schmuth; Robert Gruber; Andreas R Janecke; Peter M Elias; Maurice A M van Steensel; Ivo Nagtzaam; Michel van Geel; Peter M Steijlen; Colin S Munro; Daniel G Bradley; Colin N A Palmer; Frances J D Smith; W H Irwin McLean; Alan D Irvine Journal: Nat Genet Date: 2007-04-08 Impact factor: 38.330
Authors: Jonathan N W N Barker; Colin N A Palmer; Yiwei Zhao; Haihui Liao; Peter R Hull; Simon P Lee; Michael H Allen; Simon J Meggitt; Nicholas J Reynolds; Richard C Trembath; W H Irwin McLean Journal: J Invest Dermatol Date: 2006-09-21 Impact factor: 8.551
Authors: Mary Elizabeth Mathyer; Ashley M Quiggle; X F Colin C Wong; Simon L I J Denil; Monique G Kumar; Heather M Ciliberto; Susan J Bayliss; John E Common; Cristina de Guzman Strong Journal: Exp Dermatol Date: 2018-06-28 Impact factor: 3.960
Authors: Gabriela Queila de Carvalho-Siqueira; Galina Ananina; Bruno Batista de Souza; Murilo Guimarães Borges; Mirta Tomie Ito; Sueli Matilde da Silva-Costa; Igor de Farias Domingos; Diego Arruda Falcão; Iscia Lopes-Cendes; Marcos André Cavalcanti Bezerra; Aderson da Silva Araújo; Antônio Roberto Lucena-Araújo; Marilda de Souza Gonçalves; Sara Teresinha Olalla Saad; Fernando Ferreira Costa; Mônica Barbosa de Melo Journal: Exp Biol Med (Maywood) Date: 2019-05-12
Authors: David J Margolis; Nandita Mitra; Heather Gochnauer; Bradley Wubbenhorst; Kurt D'Andrea; Adam Kraya; Ole Hoffstad; Jayanta Gupta; Brian Kim; Albert Yan; Zelma Chiesa Fuxench; Katherine L Nathanson Journal: J Invest Dermatol Date: 2018-02-08 Impact factor: 8.551
Authors: Yuhree Kim; Maria Blomberg; Sheryl L Rifas-Shiman; Carlos A Camargo; Diane R Gold; Jacob P Thyssen; Augusto A Litonjua; Emily Oken; Maryam M Asgari Journal: J Invest Dermatol Date: 2018-11-08 Impact factor: 8.551